<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00534573</url>
  </required_header>
  <id_info>
    <org_study_id>LCK4569</org_study_id>
    <secondary_id>ISRCTN4569</secondary_id>
    <secondary_id>ISRCTN4569</secondary_id>
    <nct_id>NCT00534573</nct_id>
  </id_info>
  <brief_title>Benzamide Derivates as Treatment of Clozapine-induced Hypersalivation</brief_title>
  <acronym>CIH</acronym>
  <official_title>Comparison of Benzamide Derivates (Amisulpride, Moclobemide and Tiapride) as Treatment of Clozapine-induced Hypersalivation: Pilot Double Phase Study: Open and Double-blind</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beersheva Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tirat Carmel Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beersheva Mental Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypersalivation (sialorrhea or ptyalism) is known as a frequent, disturbing, uncomfortable
      adverse effect of clozapine therapy, and until now there is not enough effective treatment
      for this side effect leading to noncompliance.

      In previous studies it was found that substitute benzamide derivatives with higher selective
      binding to the D2/D3 dopamine receptor - amisulpride and sulpiride may be effective in
      treatment of clozapine-induced hypersalivation (CIH). Today, in psychiatric practice in
      Israel, there are four medications which belong to substitute benzamide derivatives group:
      amisulpride, sulpiride, tiapride and moclobemide. We hypothesized that antisalivation effect
      is universal for the whole group of benzamide.

      The aim of our study was to compare efficacy of amisulpride, moclobemide (reversible
      monoamine oxidase inhibitor-A (RIMAS)), and tiapride (dopamine D2 antagonist) as an
      additional possibility for management of CIH.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pilot study will be conducted in two mental health centers. In order to examine our
      hypothesis, we will use an add-on design. Into the study will be enrolled 50 patients with
      schizophrenia and schizoaffective disorder (males and females, 19-60 years old), according to
      the DSM-IV criteria, treated with clozapine and suffering from hypersalivation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hypersalivation will be assessed by subjective and objective tools. Clinical global impression (CGI) patient's self assessment will be taken as subjective tool and NHRS as an objective assessment tool.</measure>
    <time_frame>every two days</time_frame>
    <description>NHRS, CGI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CGI, NHRS</measure>
    <time_frame>two weeks</time_frame>
    <description>CGI, NHRS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Clozapine-induced Hypersalivation</condition>
  <arm_group>
    <arm_group_label>Moclobemide,</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment during 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amisulpride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comparison</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amisulpride, Moclobemide</intervention_name>
    <description>Amisulpride 400 mg/d; Moclobemide 300 mg/d every medication for 2 week aith 2 week washout</description>
    <arm_group_label>Moclobemide,</arm_group_label>
    <arm_group_label>Amisulpride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-60 years, male or female

          -  DSM-IV criteria for schizophrenia

          -  Clozapine treatment

          -  At least 2 scores on the Nocturnal Hypersalivation Rating Scale (NHRS)

        Exclusion Criteria:

          -  Evidence of organic brain damage, mental retardation, alcohol or drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladimir Lerner, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Be'er Sheva Mental Health Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anatoly Kreinin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tirat HaKarmel Mental Health Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chanoch Miodownik, MD</last_name>
    <role>Study Director</role>
    <affiliation>Be'er Sheva Mental Health Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Igor Libov</last_name>
    <role>Study Director</role>
    <affiliation>Be'er Sheva Mental Health Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander Grinshpoon, MD</last_name>
    <role>Study Director</role>
    <affiliation>Tirat HaKarmel Mental Health Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Diana Shestakova, MD</last_name>
    <role>Study Director</role>
    <affiliation>Tirat HaKarmel Mental Health Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Be'er Sheva Mental Health Center, Tirat HaKarmel Mental Health Center</name>
      <address>
        <city>Be'er Sheva, Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2007</study_first_submitted>
  <study_first_submitted_qc>September 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2007</study_first_posted>
  <last_update_submitted>July 25, 2012</last_update_submitted>
  <last_update_submitted_qc>July 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beersheva Mental Health Center</investigator_affiliation>
    <investigator_full_name>Vladimir Lerner</investigator_full_name>
    <investigator_title>A/Professor, Head of department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sialorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clozapine</mesh_term>
    <mesh_term>Sultopride</mesh_term>
    <mesh_term>Sulpiride</mesh_term>
    <mesh_term>Moclobemide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

